[ad_1]
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025.
Nichlas Pollier | Bloomberg | Getty Photographs
Shares of Novo Nordisk on Monday fell as a lot 11% after the Danish drug pharmaceutical firm mentioned a highly-anticipated trial for Alzheimer’s illness failed to satisfy its predominant purpose.
The trial examined whether or not semaglutide — the lively ingredient in Novo’s blockbuster diabetes and weight reduction medication Ozempic and Wegovy — helped sluggish development for Alzheimer’s illness.
Whereas remedy with semaglutide resulted in enchancment of Alzheimer’s disease-related biomarkers in two separate trials, this didn’t translate right into a delay of illness development, Novo mentioned in a press release Monday. The purpose had been to sluggish affected person’s cognitive decline by no less than 20%.
Analysts had previous to the outcomes known as the trials a protracted shot, whereas Novo itself had referred it as a “lottery ticket.”
Novo inventory was down 8.3% to 279 Danish kroner as of 11:50 a.m. GMT (6:50 a.m. ET).
That is breaking information. Please refresh for updates.
[ad_2]
